Friday, April 18, 2014

Aurinia to begin lupus nephritis trial in Q2

Aurinia to begin lupus nephritis trial in Q2

April 15, 2014 by · Leave a Comment 

Tweet Fresh from a US$52-million private placement, Aurinia Pharmaceuticals (TSX-V:AUP) hopes to treat its first lupus patient in the next few weeks in a Phase 2b clinical trial with its voclosporin immunosuppressant in combination with CellCept®, the standard of care for treating lupus nephritis (LN), the most severe form of lupus. “We are now well […]

Transition moves into late-stage drug development

Transition moves into late-stage drug development

March 18, 2014 by · Leave a Comment 

Tweet Transition Therapeutics (NASDAQ:TTHI; TSX:TTH) has added late-stage drug development to its operations with its acquisition from Perrigo plc (NYSE, TASE:PRGO) of neuropsychiatric drug candidate, ELND005. “We’re maybe a year away from seeing the results of ELND005 in two Phase 2 trials for the treatment of agitation/aggression in patients with mild-to-severe Alzheimer’s disease (AD), and as an […]

Boston Therapeutics planning pivotal trial

Boston Therapeutics planning pivotal trial

December 10, 2013 by · Leave a Comment 

Tweet Boston Therapeutics (OTCQB:BTHE) hopes to begin a pivotal Phase 3 trial, by the second or third quarter of 2014, of a chewable tablet that is designed to be taken before meals to reduce post-meal elevation of blood glucose in Type 2 diabetics. “Our PAZ320 drug is a potential adjunct to metformin in patients living […]

Stifel starts Tandem Diabetes at buy

Stifel starts Tandem Diabetes at buy

December 9, 2013 by · Leave a Comment 

http://www.youtube.com/watch?v=h6pWELJ4nYs’]

Tweet Stifel Nicolas has initiated coverage of Tandem Diabetes Care (NASDAQ:TNDM) with a “buy” rating and $30 price target, saying the company appears poised for dramatic growth with what “we view as a compelling differentiated platform technology, and a highly visible pipeline in the large, growing, and arguably under-penetrated insulin pump market.” Shares of Tandem […]

Aurinia readies Phase 2b trial in lupus nephritis

Aurinia readies Phase 2b trial in lupus nephritis

November 19, 2013 by · Leave a Comment 

Tweet Aurinia Pharmaceuticals (TSX-V:AUP) is preparing to begin a Phase 2b clinical trial in the first quarter of 2014 with its voclosporin immunosuppressant in combination with CellCept, the standard of care for treating lupus nephritis (LN), the most severe form of lupus. “The core of our management team executed the Aspreva Lupus Management Study, which […]

In conversation with Kelly Close

In conversation with Kelly Close

September 24, 2013 by · Leave a Comment 

http://www.youtube.com/watch?v=TQmt739ynr4′]

Tweet As president and founder of Close Concerns, a healthcare information firm focused on diabetes and obesity, Kelly Close says her passion comes from her extensive professional work as well as her personal experience, contracting Type 1 diabetes 25 years ago. Prior to starting Close Concerns, she worked in the financial sector, including stints as […]

Biolog technology cited in autism discovery

Biolog technology cited in autism discovery

June 7, 2013 by · Leave a Comment 

Tweet Closely held Biolog has announced a breakthrough in autism research made by using its advanced Phenotype MicroArray (PM) cell scanning technology. In a paper published in the journal Molecular Autism, researchers from the Greenwood Genetic Center reported a 100% correlation (87/87) of decreased metabolism of L-tryptophan in individuals with Autism Spectrum Disorders or ASDs. The metabolic alteration was not […]

Oramed readies oral insulin study in U.S.

Oramed readies oral insulin study in U.S.

May 7, 2013 by · Leave a Comment 

Tweet Oramed Pharmaceuticals (NASDAQ:ORMP) is awaiting a decision from the FDA, possibly later this week, to conduct a sub-study of the safety of its oral insulin candidate, ORMD-0801, before proceeding to a large, multi-center Phase 2 clinical trial later this year. “Approving a clinical trial in the U.S. for oral insulin is a big deal,” […]

Islet Sciences adds Dr. Eitan Akirav to SAB

Islet Sciences adds Dr. Eitan Akirav to SAB

March 27, 2013 by · Leave a Comment 

Tweet Islet Sciences (OTCBB:ISLT) has appointed Dr. Eitan Akirav to its scientific advisory board. “The expertise and deep industry relationships Dr. Akirav brings along with his significant knowledge in the field of diabetes will be quite helpful to the company moving forward,” chairman and CEO John Steel said in a statement. Dr. Akirav’s recent co-authorship […]

Byron Capital ups Transition Therapeutics to buy

Byron Capital ups Transition Therapeutics to buy

February 12, 2013 by · Leave a Comment 

Tweet Byron Capital has upgraded Transition Therapeutics (TSX:TTH; NASDAQ:TTHI) to “buy” from “hold” and raised its price target to $3.25 from $2.25 after the company reported fiscal third quarter results and updated its pipeline activities. The stock was quoted at $2.20 on Tuesday morning. Current activities include two sizable Phase 2 CNS trials testing Transition’s […]

Next Page »

Google+